OncoHost
The company develops the PROphet platform, which utilizes bioinformatic proteomic pattern recognition and artificial intelligence to predict patient response to PD-1/PD-L1 inhibitors. This blood-based diagnostic tool analyzes plasma or serum samples to provide clinicians with actionable insights for managing immunotherapy strategies. The technology is primarily targeted at oncology providers and pharmaceutical companies to assist in clinical decision-making for non-small cell lung cancer (NSCLC) and other cancer treatments.
Healthtech
Precision Oncology
Diagnostics
Biotechnology
Artificial Intelligence
Funding summary
- Total raised
- €6.6M
- Funding rounds
- 1
Investors in OncoHost
Investors on record for OncoHost. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like OncoHost?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors